CSL – UBS rates the stock as Buy

Strong plasma industry data out of the US comes as no surprise to the broker given the numbers run on a three month lag and CSL’s first half result has already told the story. The broker believes the data likely reflect ongoing movement of product from the rest of the world into the US, where prices ar higher, rather than being a proxy for plasma supply growth.

Read More